This episode of The Motley Fool's Market Checkup drills down on the days hottest headlines and plays a game of investing chicken with the world's biggest biotech. Market Checkup gives a full examination of the recent regulatory action around potential new generic threat to a big-time blockbuster drug and looks at a study questioning the benefits of robotic surgery.
In this video, health-care analysts David Williamson and Max Macaluso play the always popular game of investing chicken with Gilead Sciences. The rules of the game are simple: What would have to go wrong with Gilead before it became a bad investment? Watch and find out how competitive threats and product launches can alter a bullish investor's perception of a stock.
David Williamson owns shares of Merck. Follow David on Twitter: @MotleyDavid. Max Macaluso, Ph.D., owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.